Population-based differences in treatment outcome following anticancer drug therapies

The Lancet Oncology

Volumn 11, Issue 1, 2010, Pages 75-84

  Ma, Brigette BY ^a   Hui, Edwin P ^a   Mok, Tony SK ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYTOCHROME P450; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; DOXORUBICINOL; DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GEFITINIB; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLATINUM COMPLEX; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAXANE DERIVATIVE; UNINDEXED DRUG;

ADJUVANT THERAPY; AREA UNDER THE CURVE; ASIA; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CIGARETTE SMOKING; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; DIAGNOSTIC TEST; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENVIRONMENTAL FACTOR; FEBRILE NEUTROPENIA; GENE MUTATION; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; INCIDENCE; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PHARMACOGENETICS; POPULATION GENETICS; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SOCIOECONOMICS; STOMACH CANCER; STOMACH SURGERY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; CONTINENTAL POPULATION GROUPS; ENVIRONMENT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MALE; NEOPLASMS; PATIENT SELECTION; PHARMACOGENETICS; RISK ASSESSMENT; RISK FACTORS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 73549124318     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70160-3     Document Type: Review

References (91)

1. Boyle P., and Levin B. World Cancer Report 2008 (2008), World Health Organization, Geneva
2. Alberg A.J., Brock M.V., and Samet J.M. Epidemiology of lung cancer: looking to the future. J Clin Oncol 23 (2005) 3175-3185
3. Epplein M., Schwartz S.M., Potter J.D., and Weiss N.S. Smoking-adjusted lung cancer incidence among Asian-Americans (United States). Cancer Causes Control 16 (2005) 1085-1090
4. Bain C., Feskanich D., Speizer F.E., et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 96 (2004) 826-834
5. Shigematsu H., Lin L., Takahashi T., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97 (2005) 339-346
6. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
7. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361 (2009) 947-957
8. Porta R., Queralt C., Cardenal F., et al. Erlotinib customization based on epidermal growth factor receptor mutations in stage IV non-small-cell lung cancer patients. Proc Am Soc Clin Oncol 26 suppl (2008) Abstr 8038.
9. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
10. Sekine I., Yamamoto N., Nishio K., and Saijo N. Emerging ethnic differences in lung cancer therapy. Br J Cancer 99 (2008) 1757-1762
11. Millward M.J., Boyer M.J., Lehnert M., et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 14 (2003) 449-454
12. Goh B.C., Lee S.C., Wang L.Z., et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 20 (2002) 3683-3690
13. Mukohara T., Takeda K., Miyazaki M., Takifuji N., Terakawa K., and Negoro S. Japanese experience with second-line chemotherapy with low-dose (60 mg/M2) docetaxel in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 48 (2001) 356-360
14. Smigal C., Jemal A., Ward E., et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56 (2006) 168-183
15. Chlebowski R.T., Chen Z., Anderson G.L., et al. Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97 (2005) 439-448
16. Watlington A.T., Byers T., Mouchawar J., Sauaia A., and Ellis J. Does having insurance affect differences in clinical presentation between Hispanic and non-Hispanic white women with breast cancer?. Cancer 109 (2007) 2093-2099
17. Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295 (2006) 2492-2502
18. Kurebayashi J., Moriya T., Ishida T., et al. The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 16 suppl 2 (2007) S72-S77
19. Kiyotani K., Sasa M., Bando Y., et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 99 (2008) 995-999
20. Lim H.S., Lee H.J., Seok Lee K., Sook Lee E., Jang I.J., and Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 25 (2007) 3837-3845
21. Nowell S., Sweeney C., Winters M., et al. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 94 (2002) 1635-1640
22. Schroth W., Antoniadou L., Fritz P., et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25 (2007) 5187-5193
23. Punglia R.S., Burstein H., Winer E.P., and Weeks J.C. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst 100 (2008) 642-648
24. Hershman D., Weinberg M., Rosner Z., et al. Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst 95 (2003) 1545-1548
25. Grann V.R., Bowman N., Joseph C., et al. Neutropenia in 6 ethnic groups from the Caribbean and the US. Cancer 113 (2008) 854-860
26. Lewis L.D., Miller A.A., Rosner G.L., et al. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res 13 (2007) 3302-3311
27. Sandanaraj E., Lal S., Selvarajan V., et al. PXR Pharmacogenetics: Association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin Cancer Res 14 (2008) 7116-7126
28. Lal S., Wong Z.W., Jada S.R., et al. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics 8 (2007) 567-575
29. Lal S., Wong Z.W., Sandanaraj E., et al. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99 (2008) 816-823
30. Lal S., Sandanaraj E., Wong Z.W., et al. CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients. Cancer Sci 99 (2008) 2045-2054
31. Marsh S., Somlo G., Li X., et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 7 (2007) 362-365
32. Saito Y., Katori N., Soyama A., et al. CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenet Genomics 17 (2007) 461-471
33. Tham L.S., Holford N.H., Hor S.Y., et al. Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4α, and constitutive androstane receptor with docetaxel pharmacokinetics. Clin Cancer Res 13 (2007) 7126-7132
34. American Cancer Society. Colorectal Cancer Facts and Figures 2008-2010. http://www.cancer.org/downloads/STT/F861708_finalforweb.pdf (accessed Nov 2, 2009).
35. Shavers V.L. Racial/ethnic variation in the anatomic subsite location of in situ and invasive cancers of the colon. J Natl Med Assoc 99 (2007) 733-748
36. Artinyan A., Sun C., Bhatia S., Pigazzi A., Garcia-Aguilar J., and Kim J. Stark racial disparities in outcomes for colorectal cancer in Los Angeles County. Proc Am Soc Clin Oncol Gastrointest Cancers Symp (2009) Abstr 324.
37. Baldwin L.M., Dobie S.A., Billingsley K., et al. Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst 97 (2005) 1211-1220
38. Linardou H., Dahabreh I.J., Kanaloupiti D., et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9 (2008) 962-972
39. Braun M.S., Richman S.D., Quirke P., et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 26 (2008) 2690-2698
40. Innocenti F., Undevia S.D., Iyer L., et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22 (2004) 1382-1388
41. Toffoli G., Cecchin E., Corona G., et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24 (2006) 3061-3068
42. Ando Y., Saka H., Ando M., et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60 (2000) 6921-6926
43. Liu C.Y., Chen P.M., Chiou T.J., et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 112 (2008) 1932-1940
44. Marcuello E., Altes A., Menoyo A., Del Rio E., Gomez-Pardo M., and Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91 (2004) 678-682
45. Iyer L., Das S., Janisch L., et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2 (2002) 43-47
46. Jada S.R., Lim R., Wong C.I., et al. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 98 (2007) 1461-1467
47. Innocenti F., Grimsley C., Das S., et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12 (2002) 725-733
48. Haller D.G., Cassidy J., Clarke S.J., et al. Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 26 (2008) 2118-2123
49. Reigner B., Watanabe T., Schuller J., et al. Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. Cancer Chemother Pharmacol 52 (2003) 193-201
50. Wei X., Elizondo G., Sapone A., et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 51 (1998) 391-400
51. Yamaguchi K., Arai Y., Kanda Y., and Akagi K. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-fluorouracil. Jpn J Cancer Res 92 (2001) 337-342
52. He Y.F., Wei W., Zhang X., et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in Chinese cancer patients. J Clin Pharm Ther 33 (2008) 307-314
53. Maekawa K., Saeki M., Saito Y., et al. Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. J Hum Genet 52 (2007) 804-819
54. Popat S., Matakidou A., and Houlston R.S. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22 (2004) 529-536
55. Lecomte T., Ferraz J.M., Zinzindohoue F., et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10 (2004) 5880-5888
56. Cho H.J., Park Y.S., Kang W.K., Kim J.W., and Lee S.Y. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. Ther Drug Monit 29 (2007) 190-196
57. Marcuello E., Altes A., del Rio E., Cesar A., Menoyo A., and Baiget M. Single nucleotide polymorphism in the 5′ tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 112 (2004) 733-737
58. Marsh S., Collie-Duguid E.S., Li T., Liu X., and McLeod H.L. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 58 (1999) 310-312
59. Tsuji T., Hidaka S., Sawai T., et al. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res 9 (2003) 3700-3704
60. Moertel C.G., Fleming T., Macdonald J.S., et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122 (1995) 321-326
61. Elsaleh H., Joseph D., Grieu F., Zeps N., Spry N., and Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355 (2000) 1745-1750
62. Laurie J.A., Moertel C.G., Fleming T.R., et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7 (1989) 1447-1456
63. Jessup J.M., Stewart A., Greene F.L., and Minsky B.D. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 294 (2005) 2703-2711
64. Matsuzaka M., Fukuda S., Takahashi I., et al. The decreasing burden of gastric cancer in Japan. Tohoku J Exp Med 212 (2007) 207-219
65. Sasako M., Sano T., Yamamoto S., et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359 (2008) 453-462
66. Cuschieri A., Weeden S., Fielding J., et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 79 (1999) 1522-1530
67. Bonenkamp J.J., Songun I., Hermans J., et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 345 (1995) 745-748
68. McCulloch P.G., Ochiai A., O'Dowd G.M., Nash J.R., Sasako M., and Hirohashi S. Comparison of the molecular genetics of c-erb-B2 and p53 expression in stomach cancer in Britain and Japan. Cancer 75 (1995) 920-925
69. Gill S., Shah A., Le N., Cook E.F., and Yoshida E.M. Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J Clin Oncol 21 (2003) 2070-2076
70. Al-Refaie W.B., Tseng J.F., Gay G., et al. The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base. Cancer 113 (2008) 461-469
71. Faivre J., Forman D., Esteve J., and Gatta G. Survival of patients with oesophageal and gastric cancers in Europe. EUROCARE Working Group. Eur J Cancer 34 (1998) 2167-2175
72. Maguire A., Porta M., Sanz-Anquela J.M., Ruano I., Malats N., and Pinol J.L. Sex as a prognostic factor in gastric cancer. Eur J Cancer 32A (1996) 1303-1309
73. Sakuramoto S., Sasako M., Yamaguchi T., et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357 (2007) 1810-1820
74. Ohtsu A., Yoshida S., and Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol 24 (2006) 2188-2196
75. Lambert R., Guilloux A., Oshima A., et al. Incidence and mortality from stomach cancer in Japan, Slovenia and the USA. Int J Cancer 97 (2002) 811-818
76. McCulloch P., Nita M.E., Kazi H., and Gama-Rodrigues J. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev (2004) CD001964.
77. Cunningham D., Allum W.H., Stenning S.P., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 (2006) 11-20
78. Kelsen D.P. Postoperative adjuvant chemoradiation therapy for patients with resected gastric cancer: intergroup 116. J Clin Oncol 18 (2000) 32S-34S
79. Van Cutsem E., Moiseyenko V.M., Tjulandin S., et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24 (2006) 4991-4997
80. Ajani J.A., Faust J., Ikeda K., et al. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol 23 (2005) 6957-6965
81. Hirata K., Horikoshi N., Aiba K., et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5 (1999) 2000-2005
82. van Groeningen C.J., Peters G.J., Schornagel J.H., et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 18 (2000) 2772-2779
83. Fujita K., Yamamoto W., Endo S., et al. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. Cancer Sci 99 (2008) 1049-1054
84. Comets E., Ikeda K., Hoff P., Fumoleau P., Wanders J., and Tanigawara Y. Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients. J Pharmacokinet Pharmacodyn 30 (2003) 257-283
85. Hoskins J.M., Marcuello E., Altes A., et al. Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res 14 (2008) 1788-1796
86. Hoskins J.M., Goldberg R., Qu P., Ibrahim J.G., and McLeod H.L. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99 (2007) 1290-1295
87. Hahn K.K., Wolff J.J., and Kolesar J.M. Pharmacogenetics and irinotecan therapy. Am J Health Syst Pharm 63 (2006) 2211-2217
88. Kweekel D.M., Gelderblom H., Van der Straaten T., Antonini N.F., Punt C.J., and Guchelaar H.J. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer 99 (2008) 275-282
89. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?. Genet Med 11 (2009) 15-20
90. O'Dwyer P., Eckhardt S.G., Haller D., et al. Priorities in colorectal cancer research: recommendations from the gastrointestinal scientific leadership council of the coalition of cancer cooperative groups. J Clin Oncol 25 (2007) 2313-2321
91. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537